NeoBiotechnologies proudly offers one of the largest commercially available portfolios of hybridoma clones, hybridoma cell lines, and recombinant monoclonal antibodies. We also hold exclusive rights to a wide variety of antibodies against recognized therapeutic targets available for licensing or collaboration. The benefits of licensing a Hybridoma clone or producing from a reliable sequence extend to securing a stable supply, gaining a competitive advantage, accelerating drug development, and improving diagnostic kit development. At NeoBiotechnologies, we are committed to advancing research and innovation by providing researchers and companies with unparalleled resources and opportunities. Explore our diverse portfolio and licensing options to elevate your research and development endeavors.